Inloggad som:

MAGNETISMM-7-studien

Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.

MAGNETISMM-7-studien
A randomised, 2-arm, phase 3 study of elranatamab (PF-06863135) versus lenalidomide in patients with newly diagnosed multiple myeloma who are minimal residual disease-positive after undergoing autologous stem-cell transplantation
A randomised, 2-arm, phase 3 study of elranatamab (PF-06863135) versus lenalidomide in patients with newly diagnosed multiple myeloma who are minimal residual disease-positive after undergoing autologous stem-cell transplantation
PLACEHOLDER
Mer information om studien för vårdgivare
Behandling
Fas 3
Palliativ
Företag

Studien ändrades senast av: studyjohanna (2023-03-19)

Tillbaka till listan